TheraRadar
← Back
Data updated: May 24, 2026

IMMUNOCORE LTD

Biotech
OncologyMetabolicInfectious Disease Execution: Needs Improvement

IMMUNOCORE LTD is a biotechnology company focused on Oncology, Metabolic, Infectious Disease.

2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Novel Drugs (2022):
1 Novel Approvals 1 First-in-Class 1 Orphan Drug 1 Breakthrough

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

KIMMTRAK
Oncology

Uveal Melanoma

CD3 Approved 2022

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 93%
1 drugs Phase 3: 2 Phase 2: 2 Phase 1: 8
Metabolic 4%
0 drugs Phase 1: 1
Infectious Disease 4%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

2
Phase 3
2
Phase 2
10
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2027
Brenetafusp
Advanced Melanoma
Estimated · fresh NCT06112314
Q1 2028
Tebentafusp
Advanced Melanoma
Estimated · fresh NCT05549297

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KIMMTRAK leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/2 completed
  • • Speed: 78 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges